Treatment-resistant depression: Clinical significance, concept and management

National Medical Journal of India

Volumn 11, Issue 2, 1998, Pages 69-79

  Sharan, P ^a   Saxena, S ^b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; ISOCARBOXAZID; NORTRIPTYLINE; PHENELZINE; TRANYLCYPROMINE; VENLAFAXINE;

DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HUMAN; PATIENT CARE; PREVALENCE; PSYCHOTHERAPY; REVIEW; SOCIOECONOMICS;

ADOLESCENT; AGED; CHILD; DEPRESSION; DRUG RESISTANCE; HUMANS;

EID: 0031744848     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (152)

1. Sartorious N, Davidian H, Ernberg G, Fenton FR, Fujii I, Gastpar M, et al. Depressive disorders in different cultures. Geneva: World Health Organization, 1983.
2. Wittchen H, Knauper B, Kessler RC. Lifetime risk of depression. Br J Psychiatry 1994;165 (Suppl 26):16-22.
3. Rao AV. Unipolar and bipolar depressions - A review. Indian J Psychiatry 1984;26:99-106.
4. Sen B, Williams P. The extent and nature of depressive phenomena in primary health care: A study in Calcutta, India. Br J Psychiatry 1987;151:486-93.
5. Keller MB, Hanks DL. The natural history and heterogeneity of depressive disorders: Implications for rational antidepressant therapy. J Clin Psychiatry 1994;55 (Suppl A):25-31.
6. Trivedi JK, Dalal PK. Management of chronic and refractory depression. In: Agarwal AK, Katriyar M (eds). Affective disorders. Lucknow:King George's Medical College, 1993:102-18.
7. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. The functioning and well-being of depressed patients: Results from the medical outcomes study. JAMA 1989;262:914-20.
8. Berglund M, Nilsson K. Mortality in severe depression: A prospective study including 103 suicides. Acta Psychiatr Scand 1987;76:372-80.
9. Anonymous. Treatment of depression in India. Natl Med J India 1990;3:209-11.
10. Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164: 665-73.
11. Sharma SD. A comparison of a divided and a single dose regime of dothiepin and its therapeutic efficacy. Indian J Psychiatry 1981;23:355-9.
12. Singh G. Sintamil in the treatment of depression: A comparison of single versus divided dose administration. Indian J Psychiatry 1980;22:195-9.
13. Fava M, Davidian KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200.
14. Evans MD, Hollon SD, Derubeis RJ, Piasecki JM, Grove WM, Garvey MJ, et al. Differential relapse following cognitive therapy and pharmacotherapy for depression. Arch Gen Psychiatry 1992;49:802-8.
15. Fawcett J, Scheftner WA, Fogg L, Clark DC, Young MA, Hedeker D, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990; 147:1189-94.
16. Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-8.
17. Heimann H. Therapy resistant depressions: Symptoms and syndrome, contributions to symptomatology and syndromes. Pharmacopsychiatrie Neuropsychopharmakologie 1974;7:139-44.
18. Lehmann H. Therapy resistant depressions - A clinical classification. Pharmacopsychiatrie Neuropsychopharmakologie 1974;7:156-63.
19. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: Definition and treatment approaches. J Clin Psychiatry 1990;51 (Suppl 6):39-47.
20. Ayd FJ Jr. Lexicon of psychiatry, neurology and the neurosciences. Baltimore: Williams and Wilkins, 1995.
21. Dyck MJ. Treatment-resistant depression: A critique of current approaches. Aust N Z J Psychiatry 1994;28:34-41.
22. Nierenberg AA. A systematic approach to treatment resistant depression. J Clin Psychiatry 1992;(Monograph 10):5-8.
23. American Psychiatric Association.Diagnostic and statistical manual. Washington, DC: American Psychiatric Association, 1994.
24. Nelsen MR, Dunner DZ. Clinical and differential diagnostic aspects of treatment resistant depression. J Psychiatry Res 1995;29:43-50.
25. Reus VI. Management of treatment-resistant unipolar and chronically depressed patients. Psychiatr Clin North Am 1996;19:201-13.
26. Kupfer DJ, Spiker DG. Refractory depression: Prediction of non-response by clinical indicators. J Clin Psychiatry 1981;42:307-12.
27. Scott J, Barker WA, Eccleston D. The Newcastle chronic depression study: Patient characteristics and factors associated with chronicity. Br J Psychiatry 1988;152:28-33.
28. Keller MB, Klerman GL, Lavori PW, Coryell W, Endicott J, Taylor J. Long-term outcome of episodes of major depression: Clinical and public health significance. JAMA 1984;252:788-92.
29. Nelson JC, Mazure CM, Jatlow PI. Characteristics of desipramine-refractory depression. J Clin Psychiatry 1994;55: 12-19.
30. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-37.
31. Keller MB, Lavori PW, Endicott J, Coryell W, Klerman GL. "Double depression": Two-year follow up. Am J Psychiatry 1983;140:689-94.
32. Aronson TA, Shukla S, Hoff A, Cook B. Proposed delusional depression subtypes: Preliminary evidence from a retrospective study of phenomenology and treatment course. J Affect Disord 1988;14:69-74.
33. Fava M. Bouffides E, Pava JA, McCarthy MK, Steingard RJ, Rosenbaum JF. Personality disorder comorbidity with major depression and response to fluoxetine treatment. Psychother Psychosom 1994;62:160-7.
34. Keitner GI, Ryan CE, Miller IW, Kohn R, Epstein NB. Twelve-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression). Am J Psychiatry 1991;148:345-50.
35. Popkin MK, Callies AL, Mckenzie TB. The outcome of antidepressant use in the medically ill. Arch Gen Psychiatry 1985;42:1160-3.
36. Keller MB. Diagnostic issues and clinical course of unipolar illness. In: Frances A, Hales R (eds). Review of psychiatry. Vol. 7. Washington DC:American Psychiatric Press, 1988:188-212.
37. Akiskal HS. Factors associated with incomplete recovery in primary depressive illness. J Clin Psychiatry 1982;43:266-71.
38. Scott J, Eccleston D, Boys R. Can we predict the persistence of depression? Br J Psychiatry 1992;161:633-7.
39. Keitner GI, Ryan CE, Miller IW, Norman WH. Recovery and major depression: Factors associated with a twelve-month outcome. Am J Psychiatry 1992;149: 93-9.
40. Hickie I, Parker G. The impact of an uncaring partner on improvement in non-melancholic depression. J Affect Disord 1992;21:147-60.
41. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148:910-16.
42. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 1994;151 (Suppl):1-36.
43. Wilhelm K, Mitchell P, Boyce P, Hickie I, Brodaty H, Austin M-P, Parker G. Treatment resistant depression in an Australian context. I. The utility of the term and approaches to management. Aust N Z J Psychiatry 1994;28:14-22.
44. McEwan WG, Remick RA. Treatment-resistant depression: A clinical perspective. Can J Psychiatry 1988;33:788-92.
45. Charney DS, Nelson JC. Delusional and nondelusional unipolar depression: Further evidence of distinct subtypes. Am J Psychiatry 1981;138:328-33.
46. Sharma V, Mazmanian D, Persad E, Kueneman K. A comparison of comorbid patterns in treatment-resistant unipolar and bipolar depression. Can J Psychiatry 1995;40:270-4.
47. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, et al. Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: A double-blind partial cross-over study on the effects of oxaprotiline and fluovoxamine.Acta Psychiatr Scand 1988;78:668-75.
48. Channabasvanna SM. Drug therapy in India: Critical issues in the quality of care. Indian J Psychiatry 1996;38:67-78.
49. Shamasunder C. Prescriber's nightmare. Indian J Psychiatry 1992;34:397-8.
50. Andrade C. Psychotropic drugs: What's in a name? Indian J Psychiatry 1996; 38:182.
51. Perez-Stable EJ, Miranda J, Munoz RF, Ying YW. Depression in medical outpatients: Underrecognition and misdiagnosis. Arch Intern Med 1990;150: 1083-8.
52. Keller MB, Lavori PW, Klerman GL, Andreasen NC, Endicott J, Coryell W, et al. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 1986;43:458-66.
53. Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am 1996;19:371-86.
54. Guze BH, Baxter LR Jr, Rego J. Refractory depression treated with high doses of a monoamine oxidase inhibitor. J Clin Psychiatry 1987;48:31-2.
55. Greenhouse JB, Kupfer DJ, Frank E, Jarret DB, Rejman KA. Analysis of time to stabilization in the treatment of depression: Biological and clinical correlates. J Affect Disord 1987;13: 259-62.
56. Georgotas A, McCue RE, Friedman E, Cooper TB. Response of depressive symptoms to nortriptyline, phenelzine and placebo. Br J Psychiatry 1987;151:102-6.
57. Loo H, Ganry H, Dufour H, Guelfi JD, Malka R, Olie JP, et al. Long term use of tianeptine in 380 depressed patients. Br J Psychiatry 1992;160 (Suppl 15):61-5.
58. Goscott R, Grof P. The clinical meaning of refractory depression: A review for the clinician. Am J Psychiatry 1991;148:695-704.
59. Quitkin FM, McGrath PJ, Stewart JW, Ocepek-Welikson K, Taylor BP, et al. Chronological milestones to guide drug change: When should clinicians switch antidepressants? Arch Gen Psychiatry 1996;53:785-92.
60. Book HE. Some psychodynamics of non-compliance. Can J Psychiatry 1987;32: 115-17.
61. Meyer UA, Amrein R, Balant LP, Bertilsson L, Eichelbaum M, Guentert TW, et al. Antidepressants and drug-metabolizing enzymes - Expert group report. Acta Psychiatr Scand 1996;93:71-9.
62. Lydiard RB. Treatment-resistant depression: Treatment resistance or inadequate treatment. J Clin Psychiatry 1985;46:412-17.
63. Amsterdam JD, Maislin G, Potter L. Fluoxetine efficacy in treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:243-61.
64. Hopkinson G, Kenny F. Treatment with reserpine of patients resistant to tricyclic antidepressants. Psychiatr Clin Basel 1975;8:109-14.
65. Amsterdam JD, Berwish NJ. Treatment of refractory depression with combination reserpine and tricyclic antidepressant therapy. J Clin Psychopharmacol 1987;7:238-42.
66. Price LH, Charney DS, Heninger GR. Reserpine augmentation of desimipramine in refractory depression: Clinical and neurobiological effects.Psychopharmacology (Berlin) 1987;92:431-7.
67. Hornig-Rohan M, Wolkowitz OM, Amsterdam JD. Novel strategies for treatment resistant depression. Psychiatr Clin North Am 1996;19:387-405.
68. Cole JO, Schatzberg AF, Sniffin C. Trazadone in treatment-resistant depression: An open study. J Clin Psychopharmacol 1981;1:495-505.
69. Tyrer P. Towards rational treatment with monoamine oxidase inhibitors. Br J Psychiatry 1976;128:354-60.
70. Mallinger AG, Himmelhoch JM, Thase ME, Edwards DJ, Knopf S, et al. Plasma tranylcypromine: Relationship to pharmacokinetic variables and clinical antidepressant actions. J Clin Psychopharmacol 1990;10:176-83.
71. Fava M. Rappe SM, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF. Relapse in patients on long term fluoxetine treatment: Response to increased fluoxetine dose. J Clin Psychiatry 1995;56:52-5.
72. Austin MPV, Souza FGM, Goodwin GM. Lithium augmentation in antidepressant-resistant patients: A quantitative analysis. Br J Psychiatry 1991;159:510-14.
73. Katona CLE, Abou-Saleh MT, Harrison DA, Nairae BA, Edwards DRL, Lock T, et al. Placebo controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166:80-6.
74. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression: A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162:634-40.
75. Thase ME, Kupfer DJ, Frank E, Jarrert DB. Treatment of imipramine resistant recurrent depression. II: An open clinical trial of lithium augmentation. J Clin Psychiatry 1989;50:413-17.
76. Rybakowski JK. Lithium potentiation of antidepressants. In: Amsterdam JD (ed). Pharmacotherapy of depression. New York: Marcel Dekker, 1990:225-40.
77. Aronson R, Offman HJ, Joffe RT, Naylor D. Triiodothyronine augmentation in the treatment of refractory depression: A meta-analysis. Arch Gen Psychiatry 1996;53:842-8.
78. Thase ME, Kupfer DJ, Jarrett DB. Treatment of imipramine-resistant recurrent depression. I. An open trial of adjunctive L-triiodothyronine. J Clin Psychiatry 1989;50:385-8.
79. Schwarcz G, Halaris A, Baxter L, Escobar J, Thompson M, Young M. Normal thyroid function in desipramine nonresponders converted to responders by the addition of L-triiodothyronine. Am J Psychiatry 1984;141:1614-16.
80. Joffe RT, Singer W, Levitt AJ, McDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-93.
81. Joffe RT, Singer W. Thyroid hormone potentiation of antidepressants. In: Amsterdam JD (ed). Refractory depression. New York: Raven Press, 1991: 185-90.
82. Marangell LB, George MS, Callahan AM, Ketter TA, Pazzaglia DJ, L'Herrov TA, et al. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry 1997;54:214-22.
83. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Balansjaar BA, Kramer HJ, et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: Two controlled crossover studies with tranylcypromine versus L-5 hydroxytryptophan and nomifensine. Acta Psychiatr Scand 1988; 78:676-83.
84. Nierenberg AA, White K. What next? A review of pharmacologic strategies for treatment resistant depression. Psychopharmacol Bull 1990;26:429-60.
85. Shawcross CR, Tyrer P. The place of monoamine oxidase inhibitors in the treatment of resistant depression. In: Zohar J, Belmaker H (eds). Treatment-resistant depression. New York:PMA Press, 1987:257-68.
86. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54:269-71.
87. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994; 51:248-51.
88. Nierenberg AA, Cole JO, Glass L. Possible trazadone potentiation of fluoxetine: A case series. J Clin Psychiatry 1992;53:83-5.
89. Flint AJ, Rifat SL. The effect of sequential antidepressant treatment on geriatric depression. J Affect Disord 1996;36:95-105.
90. Thase ME, Frank E, Mallinger AG, Tracie Hamer BS, Kupfer DJ. Treatment of imipramine-resistant recurrent depression. III. Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11.
91. Price LH, Charney DS, Heninger GR. Efficacy of lithium-tranylcypromine treatment in refractory depression. Am J Psychiatry 1985;142:619-23.
92. McGrath PJ, Stewart JW, Harrison W, Quitkin FM. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor. Psychopharmacol Bull 1987;23:169-72.
93. Fulton B, Benfield P. Moclobemide: An update of its pharmacological properties and therapeutic use. Drugs 1996;52:450-74.
94. Joffe RT, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry 1994;55:24-5.
95. Stabl M, Kasas A, Blajeu B, Bajetta G, Zochling R, Holsboer-Trachster E, et al. A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory severe depression. J Clin Psychopharmacol 1995;15(Suppl):41S-45S.
96. Ebert D, Albert R, May A, Stosiek I, Raschka W. Combined SSRI-RIMA treatment in refractory depression: Safety data and efficacy. Psychopharmacology 1995;119:342-4.
97. Sunderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA, et al. High dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994;51:607-15.
98. Solyom L, Gibson RE. Fluoxetine in refractory depression. Biol Psychiatry 1990;27:461-3.
99. Beasley CM Jr, Sayler ME, Cunningham GE, Weiss AM, Masica DN. Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord 1990;20: 193-200.
100. Preskorn S. Antidepressant drug selection: Criteria and options. J Clin Psychiatry 1994;55 (Suppl A):6-22.
101. Nierenberg AA, Feighner JF, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14: 419-23.
102. Baron BM, Ogden AM, Siegel BW, Stegeman J, Ursillo RC, Dudley MW. Rapid down regulation of β-adrenoreceptors by co-administration of desimipramine and fluoxetine. Eur J Pharmacol 1988;154:125-34.
103. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-7.
104. Weilberg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report. J Clin Psychiatry 1989;50:447-9.
105. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, controlled study. Am J Psychiatry 1994;151:1372.
106. Doogan DP, Gaillard V. Sertraline: A new antidepressant. J Clin Psychiatry 1988; 49(Suppl):46-51.
107. Berlanga C, Ortega-Soto HA. A three year follow-up of a group of treatment resistant depression patients with a monoamine oxidase inhibitor/tricyclic combination. J Affect Disord 1995;34:187-92.
108. White K, Simpson GM. The combined use of the MAOIs and tricyclics. J Clin Psychiatry 1984;45 (7 Pt 2):67-9.
109. Marley E, Wozniak KM. Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibition. Psychol Med 1983;13:735-49.
110. White K, Simpson GM. Combined MAOI-tricyclic antidepressant treatment: A reevaluation. J Clin Psychopharmacol 1981;1:264-82.
111. Wharton RN, Perel JM, Dayton GL, Malitz S. A potential clinical use for methyl-phenidate (Ritalin) with tricyclic antidepressants. Am J Psychiatry 1971;127: 1619-25.
112. Flemenbaum A. Methylphenidate: A catalyst for the tricyclic antidepressants? Am J Psychiatry 1971;128:239.
113. Feighner JP, Herbstein J, Damlouji N. Combined MAOI, TCA, and direct stimulant therapy in treatment-resistant depression. J Clin Psychiatry 1985;46:206-9.
114. Davidson J, McLeod M, Law-Yone B, Linnoila M. A comparison of electroconvulsive therapy and combined phenelzine-amitryptiline in refractory depression. Arch Gen Psychiatry 1978;35:639-42.
115. Nelson JC, Mazure CM. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry 1986;143:363-6.
116. Dinan TG, Barry S. A comparison of electroconvulsive therapy with combined lithium and tricyclic combination among depressed tricyclic non-responders. Acta Psychiatr Scand 1989;80:97-100.
117. Shapira B, Lidsky D, Gorfine M, Lerer B. Electroconvulsive therapy and resistant depression: Clinical implications of seizure threshold. J Clin Psychiatry 1996; 57:32-8.
118. Devanand DP, Sackeim HA, Prudic J. Electroconvulsive therapy in the treatment-resistant patient. Psychiatr Clin North Am 1991;14:905-23.
119. Sackeim HA, Prudic J, Devanand DP, Kiersky JE, Fitzsimons L, Moody BJ, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med 1993;328:839-46.
120. Andrade C, Gangadhar BN, Subbakrishna DK, Channabasavanna SM, Pradhan N. Clinical prediction of rate of response of endogenous depression to electroconvulsive therapy. Indian J Psychiatry 1988;30:381-7.
121. Shukla GD. Electroconvulsive therapy: A review. Indian J Psychiatry 1989;31: 97-105.
122. Levitt AJ, Joffe RT, Kennedy SH. Bright light augmentation in antidepressant non-responders. J Clin Psychiatry 1991;52:336-7.
123. Dessauer M, Goetze U, Tolle R. Periodic sleep deprivation in drug-refractory depression. Neuropsychobiology 1985;13:111-16.
124. van den Hoofdakker RH, Gordijn MCM, Kasper S. Sleep deprivation in refractory depression. In: Nolen WA, Zohar J, Roose SP, Amsterdam JD (eds). Refractory depression: Current strategies and future directions. Chichester:John Wiley, 1974:129-42.
125. Ballantine HT Jr, Bouckoms AJ, Thomas EK, Giriunas IE. Treatment of psychiatric illness by stereotactic cingulotomy. Biol Psychiatry 1987;22:807-19.
126. Bouckoms AJ. The role of stereotactic cingulotomy in the treatment of intractable depression. In: Amsterdam JD (ed). Refractory depression. New York:Raven Press, 1991:233-42.
127. Ramamurthy B, Ravi R, Narayan P. Functional neurosurgery in psychiatric illness. Indian J Psychiatry 1980;22:261-4.
128. Pascual-Leone A, Rubio B, Pallardo F, Catala MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 1996;347:233-7.
129. Amsterdam JD, Rosenzweig M, Mozley PD. Assessment of adrenocortical activity in refractory depression: Steroid suppression with ketoconazole. In: Nolen WA, Zohar J, Roose SP, Amsterdam JD (eds). Refractory depression: Current strategies and future directions. Chichester:John Wiley, 1994:199-210.
130. Ghadirian AM, Engelsmann F, Dhar V, Filipini D, Keller R, Chouinard G, et al. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry 1995;37:369-75.
131. Arana GW, Santos AB, Laraia MT, McIeod-Bryant S, Beale MD, Rames LJ, et al. Dexamethasone for the treatment of depression: A randomised, placebo controlled, double-blind trial. Am J Psychiatry 1995;152:265-7.
132. Dinan TG, Lavelle E, Cooney J, Burnett F, Scott L, Dash A, et al. Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr Scand 1997;95: 58-61.
133. Kumar S, Davis RB. Dexamethasone in depressive syndromes. Indian J Psychiatry 1970;12:260-3.
134. Klaiber EL, Broverman DM, Vogel W, Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry 1979;36:550-4.
135. Sherwin BB. Estrogen and refractory depression. In: Amsterdam JD (ed). Advances in neuropsychiatry and psychopharmacalogy. Vol. 2. Refractory depression. New York:Raven Press, 1991:209-18.
136. Kaiser E, Kies N, Maass G, Schmidt H, Beach RC, Bormacher K, et al. The measurement of psychotropic effects of an androgen in aging males with psychovegetative symptomatology: A controlled double-blind study of mesterolone versus placebo. Prog Neuropsychopharmacol 1978;2:505-15.
137. Wilson IC, Prange AJ Jr, Lara PP. Methyltestosterone with imipramine in men. Conversion of depression to paranoid reaction. Am J Psychiatry 1974;131:21-4.
138. Barkai IA, Dunner DL, Gross HA, Mayo P, Fieve RR. Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder.Biol Psychiatry 1978;13:65-72.
139. Silverstone T. Response to bromocriptine distinguishes bipolar from unipolar depression. Lancet 1984;1:903-4.
140. Bouckoms AJ, Mangini L. Pergolide: An antidepressant adjuvant for mood disorders? Psychopharmacol Bull 1993;29:207-11.
141. Vuckovic A, Cohen BM, Zubenko GS. The use of captopril in treatment-resistant depression: An open trial. J Clin Psychopharmacol 1991;11:395-6.
142. Cappiello A, McDougle CJ, Malison RT, Heninger GR, Price LH. Yohimbine augmentation of fluvoxamine in refractory depression: A single-blind study. Biol Psychiatry 1995;38:765-7.
143. Pollack MH, Hammerness P. Adjunctive yohimbine for treatment in refractory depression. Biol Psychiatry 1993;33:220-1.
144. Joffe RT, Singer W, Levitt AJ. Methimazole in treatment-resistant depression. Biol Psychiatry 1992;31:1235-7.
145. Whybrow PL, Prange AJ. A hypothesis of thyroid-catecholamine receptor interaction: Its relevance to affective illness. Arch Gen Psychiatry 1981;38: 106-13.
146. Thase ME. The roles of psychosocial factors and psychotherapy in refractory depression: Missing pieces in the puzzle of treatment resistance? In: Nolen WA, Zohar J, Roose SP, Amsterdam JD (eds).Refractory depression: Current strategies and future directions. Chichester:John Wiley, 1994:129-42.
147. Dick PH, Leonie Sweeney M, Crombie IK. Controlled comparison of day-patient and out-patient treatment for persistent anxiety and depression. Br J Psychiatry 1991;158:24-7.
148. Pope HG Jr, McElroy SC, Nixon RA. Possible synergism between fluoxetine and lithium in refractory depression. Am J Psychiatry 1988;145:1292-4.
149. Geller B, Todd RD, Luby J, Botteron KN. Treatment-resistant depression in children and adolescents. Psychiatr Clin North Am 1996;19:253-67.
150. Stokes PE. Current issues in the treatment of major depression. J Clin Psychopharmacol 1993;13 (Suppl 2):2S-9S.
151. Flint AJ, Rifat SL. A prospective study of lithium augmentation in antidepressant-resistant geriatric depression. J Clin Psychopharmacol 1994;14:353-6.
152. Berga SL, Parry BL. Psychiatry and reproductive medicine. In: Kaplan HI, Sadock BJ (eds). Comprehensive textbook of psychiatry. Baltimore:Williams and Wilkins, 1995:1693-707.